The Hollings Cancer Center (HCC) Cell Evaluation &Therapy (CET) Shared Resource offers HCC investigators comprehensive analytic flow cytometry and high-speed cell sorting services and the capacity to generate human cellular and tissue-based products for use in translational research. The mission of the CET Shared Resource is to provide an integrated platform where HCC users can evaluate pre-clinical or clinical experimental data in a cell-specific manner and use the cell-manufacturing facility to bring the cellular product to patients. Directed by Kevin F. Staveley-O'Carroll, MD, PhD, with two Associate Directors, Amanda C. LaRue, PhD and Shikhar Mehrotra, PhD, this facility provides extensive expertise, an active educational platform, and development of new methodologies within the facility. The specific objectives of the HCC CET Shared Resource are to provide: Multi-parametric and multi-laser measurements including apoptosis, cell proliferation, cell cycle distribution, and immunophenotyping, as well as detection of intracellular proteins, membrane perturbations, and bioactive molecules. Expanded cell therapy and gene therapy-based bio-therapeutic products for Phase I and II clinical studies employing current cGMP as required by federal regulations. Immune monitoring services to evaluate the immune response in patients and provide data for basic laboratory experiments. Regulatory expertise in the preparation of cell and possibly gene therapy based INDs. High-speed cell sorting based on cell surface marker immunostaining and/or side-population staining. Consultation and assistance concerning experimental design, sample preparation, and data analysis. Training in the use of routine flow cytometric technology and analytical equipment. Advanced training in novel flow cytometric assays that are new and/or specific to HCC researchers' applications. New methods to assist HCC members in performing cutting-edge research. CET-supported experiments during the current CCSG project period have led to the success of more than 18 NCI-funded research project grants and more than 100 peer-reviewed publications.
The overall goal of the Hollings Cancer Center Cell Evaluation &Therapy Shared Resource is to provide cutting-edge research services in a cost-effective manner to cancer researchers and enable the development of innovative cellular-based treatments that will transform healthcare for citizens of the region and the nation.
|Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46|
|Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6|
|Podbielska, Maria; Szulc, ZdzisÅ‚aw M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039|
|Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25|
|Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95|
|Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30|
|Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7|
|Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50|
|Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203|
|Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263|
Showing the most recent 10 out of 311 publications